Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand [PDF]
, 2014 Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel and ASA in patients with ACS based on a Thai cost database.
Permsuwan, Unchalee +2 more
core +1 more source
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: an Updated Meta-Analysis [PDF]
, 2021 Mengyi Sun, Weichen Cui, Linping Li
openalex +1 more source
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Lateral medullary syndrome (LMS) is commonly associated with vertebral artery strokes, characterized by varied neurological manifestations depending on the site of the lesion. We report the positive effects of interdisciplinary rehabilitation interventions in helping achieve improved functional, psychosocial, and quality of life outcomes in a ...
Krystal Song +3 more
wiley +1 more source
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
BMC Cardiovascular Disorders, 2018 Background & Aims Ticagrelor has been acknowledged as a new oral antagonist of P2Y12-adenosine diphosphate receptor, as a strategy with more rapid onset as well as more significant platelet inhibition function in acute coronary syndrome (ACS) patients ...
Dong Wang +5 more
doaj +1 more source
Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452. [PDF]
PLoS ONE, 2018 Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma exposure of ticagrelor and TAM in patients are roughly 0.5-
Ann-Sofie Sandinge +3 more
doaj +1 more source
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction:a Danish nationwide population-based cohort study [PDF]
, 2016 OBJECTIVES: The study investigated dual antiplatelet therapy (DAPT) patterns over time and patient characteristics associated with the various treatments in a myocardial infarction (MI) population.
Broe, Anne +6 more
core +2 more sources
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]
, 2020 OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD +12 more
core +1 more source
Clinical Cardiology, Volume 49, Issue 1, January 2026.PASSIVATE‐CAP Research Overview and Flowchart. ABSTRACT Background Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques.
Zhongxiu Chen +11 more
wiley +1 more source
Journal of Interventional Cardiology, 2023 Background. Dual antiplatelet therapy with a P2Y12 inhibitor (e.g., clopidogrel and ticagrelor) and aspirin is recommended for at least one year after percutaneous coronary intervention (PCI) to prevent further myocardial infarction and stent thrombosis ...
Mohammadjavad Mehdizadeh Parizi +12 more
doaj +1 more source
Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019) [PDF]
, 2019 The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical fields are interconnected and synergized. A way to depict that innovation is by conducting a survey on patent activities.
Alcántara, Andrés R. +2 more
core +3 more sources